Designated Organic Active Ingredient Containing (doai) Patents (Class 514/1)
  • Patent number: 10653693
    Abstract: Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: May 19, 2020
    Assignees: Epizyme, Inc., Glaxosmithkline Intellectual Property Development Limited
    Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof, Lei Jin, Elayne Penebre, Olena I. Barbash
  • Patent number: 10632173
    Abstract: This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: April 28, 2020
    Assignee: FIRSTRING RESEARCH, INC.
    Inventor: Gautam Ghatnekar
  • Patent number: 10548881
    Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: February 4, 2020
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala
  • Patent number: 10478404
    Abstract: Methods, compositions, and devices to limit, modulate, insulate, and/or otherwise alter the effects of exogenous physical stimuli on cells are described herein. The cells may be removed from the body, preferably isolated, and treated ex vivo with the composition to limit the effects of physical stimuli on the cells and then returned to the patient. Alternatively, the cells may be treated in vivo. The compositions can be administered a variety of manners, such as systemically, locally or regionally.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: November 19, 2019
    Assignee: Arizona Board of Regents on behalf of the University of Arizona
    Inventor: Marvin J. Slepian
  • Patent number: 10420770
    Abstract: The present invention provides methods and compositions for improving episodic memory and treating dementia.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: September 24, 2019
    Assignee: EIP Pharma, LLC
    Inventor: John Jahangir Alam
  • Patent number: 10413522
    Abstract: The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: September 17, 2019
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Joan Massague, Adrienne Boire, Qing Chen
  • Patent number: 10406141
    Abstract: The present invention provides a compound capable of being used as an active ingredient of an anti-cancer agent. To provide an anti-cancer agent with few side effects, an object of the present invention is to provide a compound capable of selectively inhibiting the target, i.e., DOCK1, or a salt thereof. The pyridinone compound of the present invention is represented by Formula (1): wherein R1 and R2 are the same or different, and each represents C1-6 alkyl; and R3 is a group represented by, for example, Formula (3) below: wherein R5 in the group represented by Formula (3) is hydrogen.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: September 10, 2019
    Assignee: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Yoshinori Fukui, Takehito Uruno, Motomu Kanai, Shigeki Matsunaga, Takahiro Shirai, Shigeyuki Yokoyama, Teruki Honma, Mutsuko Niino, Daisuke Takaya
  • Patent number: 10385116
    Abstract: The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: August 20, 2019
    Assignee: Omniox, Inc.
    Inventors: Gregory Kapp, Laura Serwer, Natacha Le Moan, Stephen P. L. Cary
  • Patent number: 10376506
    Abstract: The present invention relates to an opioid antagonist with ?-activity for use in treatment of depressive disorder with melancholic features. The invention further relates to the combination of an opioid antagonist with ?-activity and vortioxetine for use in treatment of depressive disorder with melancholic features. The invention also relates to pharmaceutical compositions comprising an opioid antagonist with ?-activity and vortioxetine.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: August 13, 2019
    Assignee: H. LUNDBECK A/S
    Inventors: Connie Sanchez Morillo, Gennady N. Smagin
  • Patent number: 10327452
    Abstract: The present invention pertains to an efficient and large-scale process to produce a medium-chain triglyceride composition with >95% content for C8 (caprylic acid), C10 (capric acid) and C12 (lauric acid), with the content of lauric acid at about 5% or more. The process involves fractionation of fatty acid methyl esters, which are mainly derived from coconut or palm kernel, their esterification to glycerol to synthesize medium-chain triglycerides, and refining them to significantly increase purity and make them fit for human consumption. Such composition can have important uses in food and its preparation, health supplements, cosmetics, and medicine, among others.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: June 25, 2019
    Inventor: Dean A. Lao, Jr.
  • Patent number: 10251887
    Abstract: The invention relates to therapeutic applications for compositions that reduce the level of oxidative stress on cells in vivo or in vitro. The invention describes methods for improving the therapeutic properties of stem cells. The invention also provides combination therapies that are useful to balance the oxidative microenvironment of cells in vivo or in vitro.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 9, 2019
    Assignee: University of Massachusetts
    Inventor: Louis M. Messina
  • Patent number: 10208167
    Abstract: A compound comprising a cyclodextrin and a monoalkoxy polyethylene glycol linked thereto through an ether bond (a “pegylated cyclodextrin”) is disclosed, as are drug delivery vehicles and pharmaceutical formulations including the same, and methods for making the compound and the drug delivery vehicle and for delivering the drug to a patient in need thereof. The method of making includes the steps of creating either a tosylated monoalkoxy polyethylene glycol or a tosylated cyclodextrin, and either reacting the tosylated monoalkoxy polyethylene glycol with a deprotonated cyclodextrin, or reacting the tosylated cyclodextrin with a deprotonated monoalkoxy polyethylene glycol. The present pegylated cyclodextrin readily forms an inclusion compound with certain drugs to protect the drug against adverse interactions with mucin (e.g., in a mucus membrane).
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: February 19, 2019
    Assignee: The Board of Trustees of the California State University
    Inventors: Yong Ba, Kim Trang Huu Nguyen
  • Patent number: 10202428
    Abstract: H—NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H—NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H—NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H—NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: February 12, 2019
    Assignee: The Regents of the University of California
    Inventors: Stephen P. L. Cary, Elizabeth M. Boon, Emily Weinert, Jonathan A. Winger, Michael A. Marletta
  • Patent number: 10196345
    Abstract: Described herein are a series of compounds having the structure of Formula I: for use in the inhibition of MAO and uses thereof for the treatment of a barrier disease, obesity, solid epithelial cell tumor metastasis, diabetes, an auto-immune and inflammatory disease or a cardiometabolic disorder.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: February 5, 2019
    Assignees: THE UNIVERSITY OF BRITISH COLUMBIA, CENTRE FOR DRUG RESEARCH AND DEVELOPMENT
    Inventors: Edward Ewald Putnins, David Scott Grierson, Ronan F.B. Gealageas, Alice Andree Valentine Devineau, Edith Mary Dullaghan
  • Patent number: 10093961
    Abstract: The invention relates to diagnosis, detection, screening, identifying and predicting methods. In various embodiments, methods of the invention include diagnosis, detection, or screening for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject; identifying a subject that will or is likely to respond to a therapy for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia); and predicting therapeutic efficacy of a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) treatment in a subject.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: October 9, 2018
    Assignee: ESPERANCE PHARMACEUTICALS
    Inventors: Carola Leuschner, Hector Alila
  • Patent number: 10053422
    Abstract: The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: August 21, 2018
    Assignee: Pitney Pharmaceuticals Pty Limited
    Inventors: Mohammad Hossein Pourgholami, David L. Morris, Roger Aston
  • Patent number: 10047137
    Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: August 14, 2018
    Assignee: VERSITECH LIMITED
    Inventors: Zhiwei Chen, Lin Cheng, Allen Ka Loon Cheung, Jingying Zhou
  • Patent number: 9945853
    Abstract: The present disclosure highlights the relationship between extracellular mitochondrial components, optionally in combination with the secreted phospholipase A2-IIA and/or an auto-antibody, and in vivo as well as in vitro and inflammatory reactions/conditions, especially those released as a result of the degradation of a platelet. The present disclosure provides methods for determining the presence of inflammatory mediators, for limiting inflammatory reactions/conditions, for the diagnosis inflammatory reactions/conditions, for screening therapeutics for the treatment and/or the alleviation of symptoms of inflammatory reactions/conditions based on the detection or modulation of the level of these extracellular mitochondrial components.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: April 17, 2018
    Assignees: Université Laval, Hérma-Québec, University of Washington
    Inventors: Eric Boilard, Luc Boudreau, Louis Thibault, Michael Herman Gelb
  • Patent number: 9918980
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action ?-opioid receptor antagonist/?-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: March 20, 2018
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Patent number: 9913864
    Abstract: The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: March 13, 2018
    Assignee: THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE
    Inventor: Jeffrey Spees
  • Patent number: 9885083
    Abstract: Accordingly, in some embodiments methods for detecting an analyte or analytes in one or more sample(s) are provided. The methods encompass providing a solid support with an addressable marker and an associated ligand, contacting the solid substrate to a sample, thereby forming a contacted solid support, associating the contacted solid support with a FET array and detecting the electrical properties of the FET array and thereby detecting an analyte or analytes in one or more samples. In other embodiments, the sample encompasses a second addressable marker.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: February 6, 2018
    Assignee: Life Technologies Corporation
    Inventors: Scott Conradson, David Dinauer, Bin Zhao, Dmitriy Gremyachinskiy, Jason Myers, Jeffrey Rossio, Victoria Singer, Kristina Giorda
  • Patent number: 9861736
    Abstract: Methods are provided for collecting platelet-rich plasma. A disposable flow circuit is mounted to a fluid processing device having a fluid separation chamber and an injection device. A fluid containing plasma and platelets is continuously conveyed from a fluid source into the fluid separation chamber and processed to produce platelet-rich plasma. At least a portion of the platelet-rich plasma is automatically conveyed from the fluid separation chamber into the injection device, which is directly connected to a pump device such that at least a portion of the platelet-rich plasma from the fluid separation chamber is automatically conveyed into the pump device prior to being conveyed into the injection device. The injection device with the platelet-rich plasma is then detached from the disposable flow circuit.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: January 9, 2018
    Assignee: Fenwal, Inc.
    Inventors: John W. Barry, Jr., Brian C. Case, Jonathan Prendergast, Lan T. Nguyen, John Foley
  • Patent number: 9861652
    Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: January 9, 2018
    Assignees: Emory University, The University of Georgia Research Foundation, Inc.
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • Patent number: 9758786
    Abstract: Provided herein are composition for sensitizing tumors to anti-tumor therapies. The compositions include antisense oligonucleotides against TGF?2, wherein the compositions sensitize tumors to anti-tumor therapies. Also provided herein are method for treating cancer using the compositions described herein.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: September 12, 2017
    Assignee: AUTOTELIC, LLC
    Inventor: Vuong Trieu
  • Patent number: 9695462
    Abstract: The present invention is related to a method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity wherein phosphatidylinositol or lysophosphatidylinositol is used as an indicator. The present invention is also related to a method for screening an inhibitor of EL activity using phosphatidylinositol and a kit for use in the method.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: July 4, 2017
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Takashi Ono, Atsuko Yamamoto, Shuhei Shigaki
  • Patent number: 9689029
    Abstract: The invention provides systems and methods for processing samples. In a method, a reaction card is provided that has a channel network, a valve, and a micropump, all disposed within the card. The reaction card also has a collection well disposed on a surface of the card and a tubular member extending out from the card. A reaction vessel is provided and affixed to the reaction card such that the tubular member is inserted into the reaction vessel. Amplification reaction reagents and a sample are delivered into the reaction vessel, and an amplification reaction is initiated within the reaction vessel, resulting in an amplification product being disposed within the reaction vessel. The valve is opened to atmosphere, and the first micropump is activated to pump an aliquot of reaction product from the reaction vessel into the tubular member, through the channel network, and into the collection well.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: June 27, 2017
    Assignee: Caliper Life Sciences, Inc.
    Inventors: Edward H. Thorne, IV, Abbie L. Esterman
  • Patent number: 9670288
    Abstract: Methods for treating neurodegeneration, e.g., sensorineural hearing loss, or a demyelinating disease, using bisphosphonates, ERK kinase inhibitors, and osteoprotegerin (OPG) proteins or nucleic acids.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: June 6, 2017
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Konstantina Stankovic, Michael McKenna, Shyan-Yuan Kao, Albert Edge
  • Patent number: 9656986
    Abstract: In one embodiment, the present application discloses mixtures comprising (a) water in an amount of at least 1% wt/wt of the mixture; (b) a transition metal catalyst; and (c) one or more solubilizing agents; and methods for using such mixtures for performing transition metal mediated bond formation reactions.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: May 23, 2017
    Assignee: MYCELL TECHNOLOGIES, LLC
    Inventor: Volker Berl
  • Patent number: 9651562
    Abstract: Method of diagnosing and treating inflammatory bowel disease are disclosed herein. Inflammatory bowel disease can be treated and diagnosed using cathelicidin peptides and detection agents thereof. Specifically, method of treating and diagnosing Crohn's disease and ulcerative colitis are disclosed herein.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: May 16, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Hon Wai Koon, Charalabos Pothoulakis
  • Patent number: 9622947
    Abstract: The present invention relates to a foamable vehicle or cosmetic or pharmaceutical composition, comprising: (1) an organic carrier, at a concentration of 10% to 70% by weight, wherein said organic carrier concurrently comprises: (i) at least one hydrophobic organic carrier, and (ii) at least one polar solvent; (2) at least one surface-active agent; (3) water; and (4) at least one liquefied or compressed gas propellant at a concentration of 3% to 25% by weight of the total composition. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering the above-mentioned compositions to an afflicted target site.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: April 18, 2017
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov
  • Patent number: 9579321
    Abstract: The invention relates to therapeutic applications for compositions that reduce the level of oxidative stress on cells in vivo or in vitro. The invention describes methods for improving the therapeutic properties of stem cells. The invention also provides combination therapies that are useful to balance the oxidative microenvironment of cells in vivo or in vitro.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: February 28, 2017
    Assignee: University of Massachusetts
    Inventor: Louis M. Messina
  • Patent number: 9545390
    Abstract: An antiseptic composition suitable for use on skin and wounds comprising a source of an antimicrobial agent and an agent which disrupts biofilms. More, particularly the invention relates to a composition capable of providing effective antimicrobial activity while at the same time avoiding wound and skin irritation and retardation of wound healing.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: January 17, 2017
    Assignee: Convatec Technologies Inc.
    Inventors: Steven L. Percival, Phillip G. Bowler, David Parsons
  • Patent number: 9460246
    Abstract: Non-mechanistic, differential-equation-free approaches for predicting a particular non-linear, response of a system to a given input are provided in the form of systems, methods, and devices. These approaches are generally directed to a non-compartmental method of predicting a non-linear, time-dependent response of a component of a system to an input into the system. The systems, methods, and devices provide the ability to (i) reduce the cost of research and development by offering an accurate modeling of heterogeneous and complex physical systems; (ii) reduce the cost of creating such systems and methods by simplifying the modeling process; (iii) accurately capture and model inherent nonlinearities in cases where sufficient knowledge does not exist to a priori build a model and its parameters; and, (iv) provide one-to-one relationships between model parameters and model outputs, addressing the problem of the ambiguities inherent in the current, state-of-the-art systems and methods.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: October 4, 2016
    Assignee: ARRAPOI, INC.
    Inventor: Glenn A. Williams
  • Patent number: 9452148
    Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitizers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: September 27, 2016
    Assignee: Verva Pharmaceuticals Ltd
    Inventors: Gregory Royce Collier, Kenneth Russell Walder, James Alexander Campbell, Juan-Carlos Molero-Navajas, Nicky Konstantopoulos, Guy Yeoman Krippner
  • Patent number: 9453198
    Abstract: The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: September 27, 2016
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Stuart M. Chambers, Yuchen Qi, Yvonne Marissa Mica
  • Patent number: 9439979
    Abstract: Comparative gene analysis (CGA) was combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. It was found that EGFR is necessary for vector internalization and functions as a co-receptor for AAV6. The identification and characterization of AAV6's requirement of EGFR expression for high transduction activity has allowed construction of recombinant AAV6 vectors which are capable of targeting and killing specific types of head and neck tumors that because of this high EGFR activity, were until now, refractory to current therapies.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: September 13, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: John Chiorini, Melodie L. Weller, Michael Schmidt
  • Patent number: 9441199
    Abstract: Disclosed are cells exhibiting neuronal progenitor cell characteristics, and methods of making them from marrow adherent stem cells by regulating cellular pathways in the marrow adherent stem cells that are associated with glial transdifferentiation of the marrow adherent stem cells.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: September 13, 2016
    Assignee: SanBio, Inc.
    Inventor: Mari Dezawa
  • Patent number: 9377461
    Abstract: [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. [MEANS] A monoclonal antibody against a necrosis marker consisting the following amino acid sequence: (1) the amino acid sequence of any of SEQ ID NOs: 1 to 3, or (2) an amino acid sequence having substitution, deletion and/or insertion of one or several amino acid residues in the amino acid sequence of (1) or sharing a homology of 90% or more with the amino acid sequence of (1), and showing the same function, activity or property as that of the amino acid sequence of (1) as a protein.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: June 28, 2016
    Assignee: FUJIFILM Corporation
    Inventors: Sumio Sugano, Yukari Kanzaki, Tsuneo Saga, Atsushi Tsuji
  • Patent number: 9289423
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action mu-opioid receptor antagonist/kappa-opioid receptor agonist or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: March 22, 2016
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Mary Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Patent number: 9283185
    Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: March 15, 2016
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwal
  • Patent number: 9278088
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: March 8, 2016
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
  • Patent number: 9259426
    Abstract: This invention provides quinazoline derivatives represented by the structural formula: (I); wherein: R2 is hydrogen, NR?R?, C1-7 alkyl, arylC1-7 alkyl or C3-10 cycloalkyl; R4 is amino, C1-7 alkyl, C2-7 alkenyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, aryl, heterocyclic, arylalkyl, heterocyclic-substituted C1-7 alkyl or C3-10 cycloalkyl-C1-7 alkyl; R5 is hydrogen or C1-7 alkyl, or R5 and R4 together with the nitrogen atom to which they are attached form a heterocyclic ring; Y is a single bond, C1-7 alkylene, C2-7 alkenylene or C2-7 alkynylene; R6 is halogen, heteroaryl or aryl; R? and R? are each independently hydrogen, C1-7 alkyl-carbonyl or C1-7 alkyl; provided that R4 is not phenyl substituted with morpholino when R2 is H and R5 is H, and provided that when NR4R5 is piperazinyl, said NR4R5 is either non-substituted or substituted with methyl or acetyl; a pharmaceutically acceptable addition salt, a stereoisomer, a mono- or a di-N-oxide, a solvate or a pro-drug thereof, for the treatment of viral infections.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: February 16, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Ling-Jie Gao, Piet André Maurits Maria Herdewijn, Steven Cesar Alfons De Jonghe, William John Watkins, Lee Shun Chong
  • Patent number: 9259409
    Abstract: The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: February 16, 2016
    Assignee: Inceptum Research & Therapeutics, Inc.
    Inventor: Fabrizio G. Mastronardi
  • Patent number: 9243301
    Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, which is located between the non-cytotoxic protease and the Targeting Moiety; and a translocation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; wherein the Targeting Moiety is BAM, ?-endorphin, bradykinin, substance P, dynorphin and/or nociceptin. Nucleic acid sequences encoding the fusion proteins, methods of preparing same and uses thereof are also described.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: January 26, 2016
    Assignees: Allergan, Inc., Ipsen Bioinnovation Limited
    Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, Kei Roger Aoki, Joseph Francis, Lance Steward
  • Patent number: 9186370
    Abstract: Some embodiments of the present invention relate to methods and compositions for treating cancer. More embodiments include methods and compositions for modulating the activity of the Hedgehog pathway.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: November 17, 2015
    Assignee: University of South Alabama
    Inventors: Lalita Samant, Rajeev Samant, Shamik Das, Eddie Reed
  • Patent number: 9180138
    Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: November 10, 2015
    Assignees: University of Georgia Research Foundation, Inc., Emory University
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • Patent number: 9157906
    Abstract: The present invention provides methods and compositions for modulating the activity of phosphodiesterase 1B (PDE1B) in intracellular signaling pathways, including but not limited to, dopamine D1 intracellular signaling pathways. The invention also provides methods and compositions for modulating the activities of intracellular signaling molecules, including, but not limited to, DARPP-32 and GluR1 AMPA receptor, via modulation of PDE1B. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate PDE1B activity. The invention also provides methods of treating or ameliorating the symptoms of a disorder, including but not limited to a PDE1B-related disorder or a dopamine D1 receptor intracellular signaling pathway disorder, by administering a modulator of PDE1B, preferably, but not limited to, an inhibitor of PDE1B or an agent that decreases the production of PDE1B.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: October 13, 2015
    Assignees: THE ROCKEFELLER UNIVERSITY, THE CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Paul Greengard, David Repaske, Gretchen Snyder
  • Patent number: 9115183
    Abstract: Recombinant proteins capable of inducing platelet aggregation and uses thereof.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: August 25, 2015
    Assignee: CENTRE HOSPITALIER UNIVERSITAIRE DE DIJON
    Inventors: David Vandroux, Emmanuel De Maistre, Edouard Prost
  • Patent number: 9114159
    Abstract: The present invention relates to methods of altering the competence of a dendrite and/or the viability of a neuron by modulating the level of Elk-1 in a dendrite. The present invention also provides methods of altering the ATP levels in a neuron, methods of isolating at least one protein of a mitochondrial permeability transition pore complex, methods of introducing an RNA into a neuron, methods of translating an RNA in a dendrite, methods of monitoring risk of neurodegeneration of a neuron, and methods of treatment for neurodegenerative diseases.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: August 25, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James H. Eberwine, Lindy E. Barrett
  • Patent number: 9101583
    Abstract: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: August 11, 2015
    Assignee: Allergan, Inc.
    Inventors: James Chang, Patrick Hughes, Chin-Ming Chang